Advertisement
<span class="ccbnTxt"><p>MANSFIELD, Mass., Aug 04, 2011 (BUSINESS WIRE) --<p>Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the first patients have been enrolled in the DURABILITY(TM) Iliac and VISIBILITY(TM) Iliac studies. Dr. Marc Bosiers, at AZ St-Blasius, Dendermonde, Belgium, enrolled the initial patients in the DURABILITY study, while Dr. Patrick Peeters, at Imelda Hospital, Bonheiden, Belgium, was responsible for the first enrollment in the VISIBILITY study. </p> <p>The DURABILITY Iliac and VISIBILITY Iliac studies are prospective, multi-center, non-randomized studies designed to confirm the safety and effectiveness of Covidien's stent systems in treating disease in the common and/or external iliac arteries. The DURABILITY Iliac study will evaluate the Protégé<sup>(R)</sup> EverFlex<sup>(R)</sup> Self-Expanding Stent System and the Protégé<sup>(R)</sup> GPS(TM) Self-Expanding Nitinol Stent and Delivery Technology. The VISIBILITY Iliac study will evaluate the Visi-Pro<sup>(R)</sup> Balloon Expandable Stent System. </p> <p>The studies will be conducted in patients with peripheral arterial disease (P.A.D.). One of the most common vascular diseases, P.A.D. occurs when leg arteries become narrowed or blocked by plaque. These blockages can cause severe pain, limited physical mobility and non-healing leg ulcers. According to the American Heart Association, approximately eight million people in the U.S. suffer from P.A.D. </p> <p>Each study will enroll 75 patients at up to 20 sites in Europe and the U.S. The principal investigators leading the studies are Dr. Peter Faries of Mount Sinai School of Medicine, New York City, and Dr. John Rundback of Holy Name Medical Center, Teaneck, New Jersey. </p> <p>"The DURABILITY Iliac and VISIBILITY Iliac studies are highly significant," said Dr. Faries. "These trials will evaluate the effectiveness of three outstanding stents used to treat iliac artery occlusive disease, providing additional evidence of peripheral stenting as a recognized standard in the treatment of iliac artery diseases." </p> <p>"They represent unique companion studies for patients with a diverse range of symptomatic iliac atherosclerotic disease," said Dr. Rundback. "Often, complex patient anatomic patterns exist that may support preferential treatment with one stent system compared to another; the availability of data on these different and complementary stents in comparable patient populations will improve the ability to make confident and evidence-based treatment decisions when caring for these patients." </p> <p>The Visi-Pro Protégé EverFlex and Protégé GPS stents are available in the U.S. for the palliative treatment of malignant neoplasms in the biliary tree. Covidien is conducting the DURABILITY Iliac and VISIBILITY Iliac studies to generate clinical evidence to evaluate the effectiveness of the Covidien stent systems in treating P.A.D. of the iliac arteries. </p> <p>"With the high incidence of P.A.D., Covidien is committed to improving clinical outcomes and furthering the evaluation of the effectiveness of our stents systems. This is a key component in the continuum of care for the treatment of P.A.D. patients," said Joe Woody, President, Vascular Therapies, Covidien. </p> <p><b>ABOUT COVIDIEN</b></p> <p>Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit <a rel="nofollow" target="_blank" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.covidien.com&amp;esheet=6820606&amp;lan=en-US&amp;anchor=www.covidien.com&amp;index=1&amp;md5=301a1f53f625d19239adf99334072958">www.covidien.com</a> to learn more about our business. </p></span>

SOURCE

Advertisement
Advertisement